Crispr Therapeutics Ag (CRSP)

$57.99 +2.27 (4.07%)
Market Cap 5.57B
Revenue (ttm) 3.51M
Net Income (ttm) -581.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -16,569.80%
Debt to Equity Ratio 0.00
Volume 1,801,400
Avg Vol 1,909,570
Day's Range N/A - N/A
Shares Out 95.99M
Stochastic %K 88%
Beta 1.80
Analysts Strong Sell
Price Target $80.91

Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therap...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 41 561 32 77
Address:
Baarerstrasse 14, Zug, Switzerland
LiveCommander
LiveCommander Apr. 19 at 2:55 PM
Top 5 Gene Editing Stories in 2026 1. Lonvo Z Phase 3 data for HAE $NTLA 2. In vivo prime editing reaches clinic 2x 3. Pre-clinical CF prime editing data 4. $BEAM AATD arbitration 5. Nex Z enrollment/mitigation 6 $CRSP data from 6 programs within 12m
1 · Reply
The_Penguin_
The_Penguin_ Apr. 19 at 7:37 AM
$CRSP https://www.theguardian.com/science/2026/apr/07/crispr-gene-edited-wheat-toasted-bread-less-carcinogenic-acrylamide
0 · Reply
Moneyidea8
Moneyidea8 Apr. 18 at 7:23 PM
$CRSP Stars aligned for a large leg up! FDA on-board and buyout vibes are stronger!.
0 · Reply
svertical1
svertical1 Apr. 17 at 9:35 PM
$CADL $CRSP $HIMS $IBRX $RKT Short Volume exceeded 60% for 3 of the 4! IbRX had a rare decline in Short Volume! Big fail for HF’s to keep these suppressed today! They tried!
0 · Reply
svertical1
svertical1 Apr. 17 at 8:34 PM
$CRSP $HIMS $IBRX $RKT $CADL CADL- Honorable mention! Nice breakout too! 25.21+29.08=54.29 % held by Insiders/Institutions 55,020,000 X .5429=29,870,358 55,020,000-29,870,358=25,149,642 Float NOT held by I/I 14.82M Short Drug should be on market if ‘One Trial’ and ‘Mode of Action’ Makary was serious!
0 · Reply
svertical1
svertical1 Apr. 17 at 8:20 PM
$CRSP $HIMS $IBRX $RKT All great charts! CRSP IBRX HIM RKT
0 · Reply
svertical1
svertical1 Apr. 17 at 8:13 PM
$CRSP $HIMS $IBRX $RKT All had solid day! No squeeze yet but all great candidates.
0 · Reply
Stockswingalert
Stockswingalert Apr. 17 at 6:24 PM
$CLPT $CRSP 10% on CLPT NHOD Considered a win ✅🎯💰 Only one loss in the month of April so far 👇cc @Stocktwits for all the timestamps 😉😏😮‍💨
0 · Reply
B00ger
B00ger Apr. 17 at 5:15 PM
$CRSP
0 · Reply
svertical1
svertical1 Apr. 17 at 4:21 PM
$HIMS $CRSP $IBRX $RKT My 4 Top Squeeze Plays, but more importantly, All great companies regardless of squeeze math! I’d rank- $IBRX $HIMS $CRSP $RKT for return potential!
0 · Reply
Latest News on CRSP
Wall Street Is Completely Wrong About These 5 Stocks

Apr 9, 2026, 1:35 PM EDT - 10 days ago

Wall Street Is Completely Wrong About These 5 Stocks

HPQ HUT NVDA RCL

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 8:00 AM EDT - 12 days ago

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

Mar 11, 2026, 7:00 AM EDT - 5 weeks ago

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

Mar 10, 2026, 7:00 AM EDT - 5 weeks ago

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

Feb 13, 2026, 1:45 PM EST - 2 months ago

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 12, 2026, 4:30 PM EST - 2 months ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

Jan 12, 2026, 8:36 AM EST - 3 months ago

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:30 AM EST - 3 months ago

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

Dec 31, 2025, 5:06 PM EST - 3 months ago

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer

Dec 22, 2025, 12:45 PM EST - 4 months ago

CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

Dec 22, 2025, 8:30 AM EST - 4 months ago

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 5 months ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study

Nov 8, 2025, 10:03 AM EST - 5 months ago

CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

Nov 8, 2025, 9:56 AM EST - 5 months ago

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

Oct 10, 2025, 8:00 AM EDT - 6 months ago

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Oct 1, 2025, 8:00 AM EDT - 7 months ago

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

Sep 9, 2025, 4:00 PM EDT - 7 months ago

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

Sep 9, 2025, 2:22 PM EDT - 7 months ago

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

INCY XBI XLV

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Sep 2, 2025, 8:00 AM EDT - 8 months ago

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

Aug 14, 2025, 1:02 PM EDT - 8 months ago

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

AMD ARKF ARKG ARKK ARKQ ARKW ARKX

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 4:15 PM EDT - 9 months ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

The Big 3: ASML, GOOGL, CRSP

Jul 15, 2025, 12:01 PM EDT - 9 months ago

The Big 3: ASML, GOOGL, CRSP

ASML GOOG GOOGL

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

Jun 26, 2025, 7:00 AM EDT - 10 months ago

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

The Big 3: CRSP, OKLO, GME

Jun 23, 2025, 12:01 PM EDT - 10 months ago

The Big 3: CRSP, OKLO, GME

OKLO GME

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst

May 7, 2025, 2:17 PM EDT - 1 year ago

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst

These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results

May 7, 2025, 8:39 AM EDT - 1 year ago

These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

May 6, 2025, 4:01 PM EDT - 1 year ago

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 1 year ago

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

CRISPR Therapeutics Announces Transition of Chief Operating Officer

Mar 26, 2025, 4:01 PM EDT - 1 year ago

CRISPR Therapeutics Announces Transition of Chief Operating Officer

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 1 year ago

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 11, 2025, 4:01 PM EST - 1 year ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 8:30 AM EST - 1 year ago

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

Dec 9, 2024, 12:00 PM EST - 1 year ago

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 14, 2024, 8:30 AM EST - 1 year ago

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 9:01 AM EST - 1 year ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 5, 2024, 4:01 PM EDT - 1 year ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Final Trade: UAL, NKE, SLV & CRSP

May 24, 2024, 7:40 PM EDT - 2 years ago

Final Trade: UAL, NKE, SLV & CRSP

SLV NKE UAL

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

May 23, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

May 9, 2024, 8:30 AM EDT - 2 years ago

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 8, 2024, 4:00 PM EDT - 2 years ago

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

May 8, 2024, 7:00 AM EDT - 2 years ago

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 22, 2024, 4:30 PM EDT - 2 years ago

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 1, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Mar 13, 2024, 8:30 AM EDT - 2 years ago

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Final Trade: HPQ, RSG, GM, CRSP

Mar 1, 2024, 6:21 PM EST - 2 years ago

Final Trade: HPQ, RSG, GM, CRSP

GM HPQ RSG

Crispr Therapeutics CEO: Science in gene editing is moving at break-neck speed

Feb 29, 2024, 5:02 PM EST - 2 years ago

Crispr Therapeutics CEO: Science in gene editing is moving at break-neck speed

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 21, 2024, 7:30 AM EST - 2 years ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

Feb 15, 2024, 8:30 AM EST - 2 years ago

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

CRISPR Therapeutics Announces $280 Million Registered Direct Offering

Feb 13, 2024, 8:30 AM EST - 2 years ago

CRISPR Therapeutics Announces $280 Million Registered Direct Offering

LiveCommander
LiveCommander Apr. 19 at 2:55 PM
Top 5 Gene Editing Stories in 2026 1. Lonvo Z Phase 3 data for HAE $NTLA 2. In vivo prime editing reaches clinic 2x 3. Pre-clinical CF prime editing data 4. $BEAM AATD arbitration 5. Nex Z enrollment/mitigation 6 $CRSP data from 6 programs within 12m
1 · Reply
The_Penguin_
The_Penguin_ Apr. 19 at 7:37 AM
$CRSP https://www.theguardian.com/science/2026/apr/07/crispr-gene-edited-wheat-toasted-bread-less-carcinogenic-acrylamide
0 · Reply
Moneyidea8
Moneyidea8 Apr. 18 at 7:23 PM
$CRSP Stars aligned for a large leg up! FDA on-board and buyout vibes are stronger!.
0 · Reply
svertical1
svertical1 Apr. 17 at 9:35 PM
$CADL $CRSP $HIMS $IBRX $RKT Short Volume exceeded 60% for 3 of the 4! IbRX had a rare decline in Short Volume! Big fail for HF’s to keep these suppressed today! They tried!
0 · Reply
svertical1
svertical1 Apr. 17 at 8:34 PM
$CRSP $HIMS $IBRX $RKT $CADL CADL- Honorable mention! Nice breakout too! 25.21+29.08=54.29 % held by Insiders/Institutions 55,020,000 X .5429=29,870,358 55,020,000-29,870,358=25,149,642 Float NOT held by I/I 14.82M Short Drug should be on market if ‘One Trial’ and ‘Mode of Action’ Makary was serious!
0 · Reply
svertical1
svertical1 Apr. 17 at 8:20 PM
$CRSP $HIMS $IBRX $RKT All great charts! CRSP IBRX HIM RKT
0 · Reply
svertical1
svertical1 Apr. 17 at 8:13 PM
$CRSP $HIMS $IBRX $RKT All had solid day! No squeeze yet but all great candidates.
0 · Reply
Stockswingalert
Stockswingalert Apr. 17 at 6:24 PM
$CLPT $CRSP 10% on CLPT NHOD Considered a win ✅🎯💰 Only one loss in the month of April so far 👇cc @Stocktwits for all the timestamps 😉😏😮‍💨
0 · Reply
B00ger
B00ger Apr. 17 at 5:15 PM
$CRSP
0 · Reply
svertical1
svertical1 Apr. 17 at 4:21 PM
$HIMS $CRSP $IBRX $RKT My 4 Top Squeeze Plays, but more importantly, All great companies regardless of squeeze math! I’d rank- $IBRX $HIMS $CRSP $RKT for return potential!
0 · Reply
svertical1
svertical1 Apr. 17 at 4:07 PM
$CRSP Squeeze Math…..very squeezable! 7.2+66.76=73.96% of shares held by I/I 95.89 X .7396=70.92M shares held by Insiders Institutions 95.89-70.92=24.97M Real Float (shares not held by Insiders/Institutions) Shares Short=22.62M This doesn’t count Retail holdings. How do Short HF’s Cover?
0 · Reply
svertical1
svertical1 Apr. 17 at 4:01 PM
$CRSP Beautiful breakout! About time…
0 · Reply
The_Flying_Janitor
The_Flying_Janitor Apr. 17 at 3:05 PM
$CRSP I wish all the institution buyers would slow their roll until this thing is about to cross 60 and then make an entire weeks purchase at open market and launch 🚀 this thing through the ceiling…. Let’s leave 60 behind for good!
0 · Reply
WantsaYacht
WantsaYacht Apr. 17 at 2:30 PM
$CRSP Been here for 5 years. My average is the 52 week high. I’ve got another 5 if that’s what it takes.
0 · Reply
handmedown1
handmedown1 Apr. 17 at 2:28 PM
$CRSP i wonder how hard this will fall.when it hits 60
0 · Reply
burbs88
burbs88 Apr. 17 at 2:23 PM
$CRSP Volume spike 🙏
0 · Reply
Merlintrader
Merlintrader Apr. 17 at 12:17 PM
$CRSP New FDA Standards for Genome Editing https://www.merlintrader.com/new-fda-editing-rules-april2026/
0 · Reply
DragonAlgo
DragonAlgo Apr. 17 at 12:15 PM
🐉 $CRSP CALL — DragonAlgo® Signal Contract: CRSP CALL Expiry: 2026-04-17 | Strike: $55.00 | Type: CALL Option Plan (premium): Entry: $1.21 Stop: $0.87 TP1: $1.57 TP2: $2.06 TP3: $2.90 🔗 https://dragonalgo.com
0 · Reply
handmedown1
handmedown1 Apr. 17 at 11:41 AM
$CRSP cant ever get over 60 LameAF
0 · Reply
burbs88
burbs88 Apr. 17 at 10:40 AM
$CRSP Historically, for whatever reason, the stock loves Friday.
0 · Reply
StockCaptain7
StockCaptain7 Apr. 17 at 12:00 AM
$GNPX $XBI $IBB $CRSP
1 · Reply
DegenStock
DegenStock Apr. 16 at 2:40 PM
$CRSP sigh… just when things were getting better. Whatever, 2H 2026 data readouts is where the real price action will begin, until then it’ll probably just keep fluctuating between this range
0 · Reply